ReviewJACC. Basic to translational science2024
Towards Metabolomic-Based Precision Approaches for Classifying and Treating Heart Failure.
Review in JACC. Basic to translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Innovative Advances in Non-Invasive Detection Technologies for Heart Failure: Synergistic Application of Multimodal Sensing and Intelligent Algorithms.Reviews in cardiovascular medicine · 2026Review
- The Use of Metabolomes in Risk Stratification of Patients with Heart Failure: A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Review
- Translating Mechanistic Insights Into Action and Revealing New Pathways: Machine Learning Approaches in Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2026Review
- Metabolomics-Driven Precision Prevention and Treatment of Heart Failure with Traditional Chinese Medicine: From Mechanistic Insights to Metabolic Network Regulation.Drug design, development and therapy · 2026Review
- Lipid, Metabolomic and Gut Microbiome Profiles in Long-Term-Hospitalized Cardiac Patients-An Observational and Retrospective Study.Diagnostics (Basel, Switzerland) · 2025Article
- Metabolomic Biomarkers in Heart Failure: A Systematic Review of Diagnostic and Prognostic Significance.Cureus · 2025Review
- Roles of Autophagy and Oxidative Stress in Cardiovascular Disease.Antioxidants (Basel, Switzerland) · 2025Review
- Review
- IL-22 Attenuates Pressure Overload-Induced Heart Failure and Inflammation.Journal of cardiovascular translational research · 2025Article
- The clinical impact of mitochondrial autophagy on very late-onset recurrence after catheter ablation for atrial fibrillation.European heart journal open · 2025Article
- Metabolomic profiling in heart failure as a new tool for diagnosis and phenotyping.Scientific reports · 2025Article
- Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review.Cureus · 2025Review
- Metabolic and Pharmacokinetic Profiling of a Ketone Ester by Background SGLT2 Inhibitor Therapy in HFrEF.JACC. Basic to translational science · 2025Article
- A metabolomics study reveals potential plasma biomarkers for predicting post-infarction left ventricular remodeling: findings from the metabolights database.Frontiers in cardiovascular medicine · 2025Article
- Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes.Clinical pharmacology : advances and applications · 2025Review
- Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.Current treatment options in cardiovascular medicine · 2025Review
- Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.Circulation. Heart failure · 2024Article
- Causal Associations Between Human Blood Metabolites and Cardio-Cerebrovascular Diseases: A Mendelian Randomisation Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Both heart failure and cardiometabolic disease are on the rise, and abnormal cardiac and peripheral metabolism are central to the syndrome of heart failure. Advances in metabolomic profiling have improved our understanding of the heart's metabolic flexibility in patients with and without heart failure. Prior studies have noted patients with heart failure display metabolomic profiles associated with marked abnormalities in the metabolism of fatty acids, branched-chain amino acids, ketones, and glucose compared with control subjects. Metabolomics can highlight specific pathways that are dysregulated; however, other metabolites beyond those related to fuel metabolism may also play a role in precision-medicine approaches. Novel approaches include metabolic flux studies, spatial and single-cell analysis, serial monitoring of treatment response, and integration with other -omics data. The goal of these innovative approaches should be to harness metabolomic technologies to affect precision care for patients with heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.